It has been suggested that hormones released after nutrient absorption, such as glucose-
dependent insulinotropic peptide (GIP) and glucagon-like peptide 2 (GLP-2), could be�…

Abstract Background Glucagon-like peptide-2 (GLP-2) and glucose-dependent
insulinotropic polypeptide (GIP) both inhibit bone resorption in humans but the underlying�…

Type 1 diabetes mellitus is associated with a high risk for bone fractures. Although bone
mass is reduced, bone quality is also dramatically altered in this disorder. However, recent�…

Introduction. Hypoglycemic drugs affect the bone quality and the risk of fractures in patients
with type 2 diabetes mellitus (T2DM). We aimed to investigate the effects of glucagon‐like�…

The impact of antidiabetic drugs on bone metabolism is drawing increasing attention due to
the discovery of a correlation between type 2 diabetes mellitus (T2DM) and osteoporosis�…

Context The gut-derived incretin hormones glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide 1 (GLP-1) have been suggested to play a role in bone�…

Diabetes mellitus and osteoporosis are closely related and have complex influencing
factors. The impact of anti-diabetic drugs on bone metabolism has received more and more�…

Background Diabetes-associated osteoporosis are partly caused by accumulation of
advanced glycation endproducts (AGEs). Glucagon-like peptide-1 (GLP-1) has been shown�…

Background: In humans, the pronounced postprandial reduction in bone resorption
(decreasing bone resorption markers by around 50%) has been suggested to be caused by�…

Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of
fracture, poor bone healing and other skeletal complications. In addition, some anti-diabetic�…